Sichuan Baili Pharmaceutical Co., Ltd. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
6 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 3 with minor changes only.
- Minor: BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment · EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) Enrollment closed, study ongoing
- Notable: BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line · Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) Recruitment opened
- Notable: BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) Recruitment opened
- Notable: BL-M08D · Locally Advanced or Metastatic Melanoma and Other Solid Tumors Recruitment opened
- Minor: BL-M07D1 · Recurrent or Metastatic Gynecologic Malignancies Enrollment increased: 138 → 158 participants
- Minor: BL-B01D1 With Chemotherapy of Physician's Choice · Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) Enrollment closed, study ongoing
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 43 | |
| Phase 1/2 | 19 | |
| Phase 2 | 35 | |
| Phase 2/3 | 8 | |
| Phase 3 | 26 |
Disease areas by active trials, top 10 of 32
Lung Cancer (31) · Non-Small Cell Lung Cancer (NSCLC) (26) · Breast Cancer (23) · Head & Neck Cancer (19) · Esophageal Cancer (7) · HER2-Positive Cancer (7) · Colorectal Cancer (6) · Non-Hodgkin Lymphoma (6) · Bladder Cancer (5) · Leukemia (5)
Get alerts when Sichuan Baili Pharmaceutical Co., Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.